New tool helps physicians get on the front end of CVD.
While there are already a number of ways to assess whether patients are at risk for CAD, the literature suggests these tests may be too burdensome to be done as often as they should. However the FDA has just approved a new screening procedure that could remove at least some of the barriers. Additionally, early data suggest that the new screening test--which measures cholesterol in the skin--gives physicians new information that can help them make more informed decisions on which patients need further tests or intervention.